Table 3 Glaucoma medications.

From: Outcomes of phacoemulsification and endoscopic cyclophotocoagulation performed with dual blade ab interno trabeculectomy or trabecular micro-bypass stent insertion

Glaucoma medications

PEcK

ICE-1

p value (between groups)*

N

Mean (±SD)

Mean reduction from baseline (±SD)

p value (from baseline)*

N

Mean (±SD)

Mean reduction from baseline (±SD)

p value (from baseline)*

Baseline

53

3.3 (1.3)

  

23

1.7 (0.93)

  

<0.001*

6 weeks

48

1.6 (1.3)

1.7 (1.3)

<0.001*

21

0.52 (0.75)

1.2 (0.76)

<0.001*

0.08

3 months

21

1.3 (1.1)

1.8 (1.2)

<0.001*

15

0.40 (0.51)

1.3 (0.61)

<0.001*

0.11

6 months

35

1.7 (1.2)

1.7 (1.2)

<0.001*

19

0.54 (0.75)

1.3 (0.52)

<0.001*

0.07

12 months

17

1.7 (1.2)

1.6 (1.5)

<0.001*

12

0.94 (0.94)

0.97 (0.66)

<0.001*

0.10

  1. Mean number of glaucoma medications and mean reduction in reduction in glaucoma medications at postoperative week 6, months 3, 6, and 12 in the phacoemulsification, endoscopic cyclophotocoagulation, and dual blade ab interno trabeculectomy (PEcK) and the phacoemulsification, endoscopic cyclophotocoagulation, and trabecular micro-bypass stent (ICE-1) groups. Significance was calculated from baseline for each procedure individually, and between the relative reductions in glaucoma medications at each time point for the two procedures.
  2. *Statistical significance.
Back to article page